Knight Therapeutics Announces Relaunch of AKYNZEO® in
MONTREAL, July 04. 10, 2022 (GLOBE NEWSWIRE) — Knight Therapeutics Inc., (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, today announced that its Brazilian subsidiary, United Medical Ltd., is taking over its commercial activities in its own right and relaunched AKYNZEO® (netupitant / palonosetron) in Brazil.
On May 12, 2022, Knight and Helsinn Healthcare SA (“Helsinn”) announced that they had entered into an exclusive license, distribution and supply agreement for AKYNZEO oral/IV® in Canada, Brazil, Argentina, Uruguay and Paraguay, and ALOXI® oral/IV (palonosetron) in Canada (the “products”).
AKYNZEO® is approved for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. According to IQVIA, AKYNZEO’s sales® in Canada and Brazil were around $7 million in 2021.
“We are proud to continue to provide patients and physicians with cutting-edge, guideline-recommended information 1,2,3 treatments like AKYNZEO® to help alleviate the debilitating effects of chemotherapy-induced nausea and vomiting,” said Samira Sakhia, President and CEO of Knight. « AKYNZEO® is synergistic with our existing oncology portfolio and will leverage the existing commercial and medical footprint.”
AKYNZEO® is the first and only 5-HT3 and NK1 fixed combination of receptor antagonists approved for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. A single dose of AKYNZEO® given with dexamethasone has been shown to be effective in preventing chemotherapy-induced nausea and vomiting for up to 5 days. AKYNZEO® oral is approved and marketed in Canada for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy and the prevention of acute nausea and vomiting associated with moderately emetogenic cancer therapy that is not controlled by 5-HT3 receptor antagonist alone in adults. AKYNZEO® oral is also approved and marketed in Argentina and Brazil for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc. shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s website at www.gud-knight.com or www.sedar.com.
This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. believes that the assumptions on which these forward-looking statements are based are reasonable at the time they were made, but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be erroneous. Factors and risks that could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and Knight Therapeutics Inc.’s Annual Information Form for the fiscal year ended December 31, 2021, as posted on www. sedar.com. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information or future events, except as required by law.
1 Roila F et al. Anne Oncol. 2016 Sep;27(supplement 5):v119-v133. MASCC/ESMO Antiemetic Guideline 2016 V.1.4 last updated July 2019. Available at: http://www.mascc.org/;
2 Hesketh J et al. J Clin Oncol. 2020 Aug 20;38(24):2782-2797. doi: 10.1200/JCO.20.01296. published online July 13, 2020;
3 NCCN: National Comprehensive Cancer Control Network; NCCN Clinical Practice Guidelines in Oncology; Edition 2.2022. Available at: www.nccn.org